Dosing and uses of Ecoza (econazole topical)
Adult dosage forms and strengths
topical cream
- 1%
topical foam
- 1% (Ecoza)
Tinea Fungal Infections & Cutaneous Candidiasis
Indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum; also indicated for treatment of cutaneous candidiasis, and in the treatment of tinea versicolor
Tinea pedis, cruris, corporis, versicolor: Apply cream to affected area(s) qDay
Cutaneous candidiasis: Apply cream to affected area(s) BId
Treatment duration
- Tinea cruris, corporis, versicolor, cutaneous candidiasis: Apply x 2 weeks
- Tinea pedis: Apply x4 weeks
Interdigital Tinea Pedis
Indicated for interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum
Ecoza: Apply foam topically to affected area(s) qDay x4 weeks
Administration
Continue full treatment duration of regimen even after infection clears to complete therapy
Pediatric dosage forms and strengths
topical cream
- 1%
topical foam
- 1% (Ecoza)
Tinea Fungal Infections & Cutaneous Candidiasis
Indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum; also indicated for treatment of cutaneous candidiasis, and in the treatment of tinea versicolor
<3 months: Safety and efficacy not established
Tinea pedis, cruris, corporis, versicolor: Apply cream to affected area(s) qDay
Cutaneous candidiasis: Apply cream to affected area(s) BId
Treatment duration
- Tinea cruris, corporis, versicolor, cutaneous candidiasis: Apply x 2 weeks
- Tinea pedis: Apply x4 weeks
Interdigital Tinea Pedis
Indicated for interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum
<12 years: Safety and efficacy not established
≥12 years (Ecoza): Apply foam topically to affected area(s) qDay x4 weeks
Administration
Continue full treatment duration of regimen even after infection clears to complete therapy
Ecoza (econazole topical) adverse (side) effects
1-10%
Erythema (3%)
Frequency not defined
Burning and stinging sensations
Pruritus
Warnings
Contraindications
Hypersensitivity
Pregnancy and lactation
Pregnancy category: C
Lactation: excretion in milk unknown; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Ecoza (econazole topical)
Mechanism of action
Fungistatic in action but may be fungicidal in high concentrations or against very susceptible organisms
Appears to exert its antifungal and antibacterial activity by altering cellular membranes and interfering with intracellular enzymes
Pharmacokinetics
Absorbed: minimaL
Peak Plasma: <1 ng/mL (applied to intact skin); <20 ng/mL (applied to skin stripped of the stratum corneum)
Excretion: urine & feces (<1%)
